Advertisement

Neuroscience and Behavioral Physiology

, Volume 44, Issue 4, pp 376–383 | Cite as

Mechanisms of Protection of the Brain from Ischemic Injury by Components of Tea

Article
  • 90 Downloads

Clinical physiology data and experimental results have identified the antiatherogenic, antiaggregant, antioxidant, and anti-inflammatory actions of substances present in tea. The effects of tea and its components have been described in relation to both long-term and single dosage. The roles of catechins and the specific amino acid L-theanine in the possible mechanisms of protection and prophylaxis of cerebrovascular pathologies have been demonstrated. Data are presented showing that regular consumption of green or black tea significantly decreases the risk of developing pathological changes in the cardiovascular system.

Keywords

tea cardiovascular diseases ischemic stroke neuroprotection theanine catechins 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. D. Denisenko, “Autoimmune complexes of lipoprotein-antibody and their role in atherogenesis,” Med. Akad. Zh., 7, No. 1, 38–44 (2007).Google Scholar
  2. 2.
    M. A. Zukhurova, A. V. Starkov, A. V. Starovoit, et al., “Hypoxic and pharmacological preconditioning as a mechanism of protection in focal cerebral ischemia in rats,” Regionarn. Krovoobrash. Mikrotsirkul., 9, No. 3, 84–89 (2010).Google Scholar
  3. 3.
    M. A. Zukhurova, A. A. Barkovskaya, V. M. Tsverina, and T. D. Vlasov, “Mechanisms of the neuroprotective effect of the green tea component L-theanine,” Regionarn. Krovoobrash. Mikrotsirkul., 9, No. 4, 67–71 (2010).Google Scholar
  4. 4.
    V. A. Nagornev, “Current views of the pathogenesis of atherosclerosis,” Med. Akad. Zh., 7, No. 1, 12–22 (2007).Google Scholar
  5. 5.
    V. I. Skvortsova, “Mechanisms of the harmful effects of cerebral ischemia and neuroprotection,” Vestnik Ros. Akad. Med. Nauk., 11, 74–81 (2003).Google Scholar
  6. 6.
    A. V. Fonyakin and L. A. Geraskina, “Antiplatelet therapy in the secondary prophylaxis of ischemic stroke,” Nevrol. Neiropsikh. Psikhosomat., No. 3–4, 58–63 (2009).Google Scholar
  7. 7.
    M. Antonello, D. Montemurro, M. Bolognesi, et al., “Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts,” Am. J. Hypertens., 20, No. 12, 1321–1328 (2007).PubMedCrossRefGoogle Scholar
  8. 8.
    L. Arab, W. Liu, and D. Elashoff, “Green and black tea consumption and risk of stroke: a meta-analysis,” Stroke, 40, No. 5, 1786–1792 (2009).PubMedCrossRefGoogle Scholar
  9. 9.
    A. Augustyniak, A. Bylinska, and E. Skrzydlewska, “Age-dependent changes in the proteolytic-antiproteolytic balance after alcohol and black tea consumption,” Toxicol. Mech. Meth., 21, No. 3, 209–215 (2011).CrossRefGoogle Scholar
  10. 10.
    G. A. Batista, C. L. Cunha, M. Scartezini, et al., “Prospective double-blind crossover study of Camellia sinensis (green tea) in dyslipidemias,” Arq. Bras. Cardiol., 93, No. 2, 128–134 (2009).CrossRefGoogle Scholar
  11. 11.
    A. Basu, K. Sanchez, M. J. Leyva, et al., “Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome,” J. Am. Coll. Nutr., 29, No. 1, 31–40 (2010).PubMedCrossRefGoogle Scholar
  12. 12.
    D. H. Belitz and W. Grosch, Quimica de los Alimentos, Acribia, Zaragoza (1997).Google Scholar
  13. 13.
    M. Blanco, M. Rodriguez-Yáñez, T. Sobrino, et al., “Platelets, inflammation, and atherothrombotic neurovascular disease: the role of endothelial dysfunction,” Cerevasc. Dis., 20, Suppl. 2, 32–39 (2005).CrossRefGoogle Scholar
  14. 14.
    C. Cabrera, R. Artacho, and R. Giménez, “Beneficial effects of green tea – a review,” J. Am. Coll. Nutr., 25, No. 2, 79–99 (2006).PubMedCrossRefGoogle Scholar
  15. 15.
    G. Cao, E. Sofic, and R. Prior, “Antioxidant capacity of tea and common vegetables,” J. Agric. Food Chem., 44, 3426–3431 (1996).CrossRefGoogle Scholar
  16. 16.
    K. Y. Chyu, S. M. Babbidge, X. Zhao, et al., “Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice,” Circulation, 109, No. 20, 2448–2453 (2004).PubMedCrossRefGoogle Scholar
  17. 17.
    S. J. Duffy, J. F. Keaney, M. Holbrook, et al., “Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease,” Circulation, 104, No. 2, 151–156 (2001).PubMedCrossRefGoogle Scholar
  18. 18.
    N. Egashira, N. Hayakawa, M. Osajima, et al., “Involvement of GABA(A) receptors in the neuroprotective effect of theanine on focal cerebral ischemia in mice,” J. Pharmacol. Sci., 105, No. 2, 211–214 (2007).PubMedCrossRefGoogle Scholar
  19. 19.
    N. Egashira, N. Ishigami, F. Pu, et al., “Theanine prevents memory impairment induced by repeated cerebral ischemia in rats,” Phytother. Res., 22, No. 1, 65–68 (2008).PubMedCrossRefGoogle Scholar
  20. 20.
    K. H. Ekborg-Ott, A. Tylor, and D. W. Armstrong, “Varietal differences in the total and enantiomeric composition of theanine in tea,” J. Agric. Food Chem., 45, 353–357 (1997).CrossRefGoogle Scholar
  21. 21.
    H. N. Graham, “Green tea composition, consumption, and polyphenol chemistry,” Prev. Med., 21, No. 3, 334–350 (1992).PubMedCrossRefGoogle Scholar
  22. 22.
    J. M. Hodgson, I. B. Puddey, T. A. Mori, et al., “Effects of regular ingestion of black tea on haemostasis and cell adhesion molecules in humans,” Eur. J. Clin. Nutr., 55, No. 10, 881–886 (2001).PubMedCrossRefGoogle Scholar
  23. 23.
    J. M. Hodgson, I. B. Puddey, V. Burke, et al., “Regular ingestion of black tea improves brachial artery vasodilator function,” Clin. Sci. (London), 102, No. 2, 195–201 (2002).CrossRefGoogle Scholar
  24. 24.
    M. H. Hong, M. H. Kim, H. J. Chang, et al., “Epigallocatechin-3-gallate inhibits monocyte chemotactic protein-1 expression in endothelial cells via blocking NF-κB signaling,” Life Sci., 80, 1957–1965 (2007).PubMedCrossRefGoogle Scholar
  25. 25.
    S. H. Ihm, J. O. Lee, S. J. Kim, et al., “Catechin prevents endothelial dysfunction in the prediabetic stage of OLETF rats by reducing vascular NADPH oxidase activity and expression,” Atherosclerosis, 206, No. 1, 47–53 (2009).PubMedCrossRefGoogle Scholar
  26. 26.
    S. Inami, M. Takano, M. Yamamoto, et al., “Tea catechin consumption reduces circulating oxidized low-density lipoprotein,” Int. Heart. J., 48, No. 6, 725–732 (2007).PubMedCrossRefGoogle Scholar
  27. 27.
    J. Jankun, M. Skotnicka, W. Lysiak-Szydlowska, et al., “Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea,” Int. J. Mol. Med., 27, No. 4, 525–529 (2011).PubMedCrossRefGoogle Scholar
  28. 28.
    Y. R. Jin, J. H. Im, E. S. Park, et al., “Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity,” J. Cardiovasc. Pharmacol., 51, No. 1, 45–54 (2008).PubMedCrossRefGoogle Scholar
  29. 29.
    N. Jochmann, M. Lorenz, A. Krosigk, et al., “The efficacy of black tea in ameliorating endothelial function is equivalent to that of green tea,” Brit. J. Nutr., 99, 863–868 (2008).PubMedCrossRefGoogle Scholar
  30. 30.
    T. Kakuda, “Neuroprotective effects of the green tea components theanine and catechins,” Biol. Pharm. Bull., 25, No. 12, 1513–1518 (2002).PubMedCrossRefGoogle Scholar
  31. 31.
    T. Kakuda, A. Nozawa, A. Sugimoto, and H. Niino, “Inhibition by theanine of binding of [3H]AMPA, [3H]kainate, and [3H]MDL 105.519 of glutamate receptors,” Biosci. Biotech. Biochem., 66, No. 12, 2683–2686 (2002).CrossRefGoogle Scholar
  32. 32.
    W. S. Kang, I. H. Lim, D. Y. Yuk, et al., “Antithrombotic activities of green tea catechins and (–)-epigallocatechin gallate,” Thromb. Res., 96, No. 3, 229–237 (1999).PubMedCrossRefGoogle Scholar
  33. 33.
    W. S. Kang, K. H. Chung, J. H. Chung, et al., “Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase,” J. Cardiovasc. Pharmacol., 38, No. 6, 875–884 (2001).PubMedCrossRefGoogle Scholar
  34. 34.
    S. O. Keli, M. G. Hertog, E. J. Feskens, and D. Kromhout, “Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study,” Arch. Intern. Med., 156, No. 6, 637–642 (1996).PubMedCrossRefGoogle Scholar
  35. 35.
    J. E. Klaunig, Y. Xu, C. Han, L. M. Kamendulis, et al., “The effect of tea consumption on oxidative stress in smokers and nonsmokers,” Proc. Soc. Exp. Biol. Med., 220, No. 4, 249–254 (1999).PubMedCrossRefGoogle Scholar
  36. 36.
    S. C. Langley-Evans, “Antioxidant potential of green and black tea determined using the ferric reducing power (FRAP) assay,” Int. J. Food Sci. Nutr., 51, No. 3, 181–188 (2000).PubMedCrossRefGoogle Scholar
  37. 37.
    S. C. Larsson, S. Männistö, M. J. Virtanen, et al., “Coffee and tea consumption and risk of stroke subtypes in male smokers,” Stroke, 39, No. 6, 1681–1687 (2008).PubMedCrossRefGoogle Scholar
  38. 38.
    W. Lee, W.-K. Min, S. Chun, et al., “Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers,” Clin. Biochem., 38, 84–87 (2005).PubMedCrossRefGoogle Scholar
  39. 39.
    W. Liang, A. H. Lee, C. W. Binns, et al., “Tea consumption and ischemic stroke risk: a case-control study in southern China,” Stroke, 40, No. 7, 2480–2485 (2009).PubMedCrossRefGoogle Scholar
  40. 40.
    P. Libby, P. M. Ridker, and A. Maseri, “Inflammation and atherosclerosis,” Circulation, 105, No. 9, 1135–1143 (2002).PubMedCrossRefGoogle Scholar
  41. 41.
    G. Lill, S. Voit, K. Schrör, and A. A. Weber, “Complex effects of different green tea catechins on human platelets,” FEBS Lett., 546, No. 2–3, 265–270 (2003).PubMedCrossRefGoogle Scholar
  42. 42.
    G. Y. Lip and S. J. Edwards, “Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis,” Thromb. Res., 118, No. 3, 321–333 (2006).PubMedCrossRefGoogle Scholar
  43. 43.
    J. Liu, C. Ying, Y. Meng, et al., “Green tea polyphenols inhibit plasminogen activator inhibitor-1 expression and secretion in endothelial cells,” Blood Coag. Fibrin., 20, No. 7, 552–557 (2009).CrossRefGoogle Scholar
  44. 44.
    M. Lorenz, K. Stangl, and V. Stangl, “Vascular effects of tea are suppressed by soy milk,” Atherosclerosis, 206, No. 1, 31–32 (2009).PubMedCrossRefGoogle Scholar
  45. 45.
    M. Maruyama and K. Takeda, “Electrophysiologically potent noncompetitive glutamate antagonists at crayfish neuromuscular junctions are also potent inhibitors of [3H]MK801 binding to synaptic membranes from rat central nervous system,” Comp. Biochem. Physiol., 107, 105–110 (1994).Google Scholar
  46. 46.
    M. Mizugaki, F. Ishizawa, T. Yamazaki, and T. Hishinuma, “Epigallocatechin gallate increases the prostacyclin production of bovine aortic endothelial cells,” Prost. Lipid. Mediat., 62, 157–164 (2000).CrossRefGoogle Scholar
  47. 47.
    K. Nakagawa and T. Miyazawa, “Absorption and distribution of tea catechin, (–)-epigallocatechin-3-gallate, in the rat,” J. Nutr. Sci. Vitaminol. (Tokyo), 43, No. 6, 679–684 (1997).CrossRefGoogle Scholar
  48. 48.
    J. Oyama, T. Maeda, K. Kouzuma, et al., “Green tea catechins improve human forearm endothelial dysfunction and have antiatherosclerotic effects in smokers,” Circ. J., 74, No. 3, 578–588 (2010).PubMedCrossRefGoogle Scholar
  49. 49.
    J. P. Reis, C. M. Loria, O. M. Steffen, et al., “Coffee, decaffeinated coffee, caffeine, and tea consumption in young adulthood and atherosclerosis later in life: the CARDIA study,” Arterioscler. Thromb. Vasc. Biol., 30, No. 10, 2059–2066 (2010).PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    M. Reto, M. E. Figueira, H. M. Felipe, and C. M. Almeida, “Chemical composition of green tea (Camellia sinensis) infusions commercialized in Portugal,” Plant Foods Hum. Nutr., 62, No. 4, 139–144 (2007).PubMedCrossRefGoogle Scholar
  51. 51.
    L. Ryan and S. Petit, “Addition of whole, semiskimmed, and skimmed bovine milk reduces the total antioxidant activity of black tea,” Nutr. Res., 30, No. 1, 14–20 (2010).PubMedCrossRefGoogle Scholar
  52. 52.
    R. L. Sacco, R. Adams, G. Albers, et al., “Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack,” Stroke, 37, No. 2, 577–617 (2006).PubMedCrossRefGoogle Scholar
  53. 53.
    Y. Sakato, “The chemical constituents of tea: III. A new amide theanine,” Nippon Nogeikagaku Kaishi, 23, 262–267 (1949).CrossRefGoogle Scholar
  54. 54.
    Y. Sato, H. Nakatsuka, T. Watanabe, et al., “Possible contribution of green tea drinking habits to the prevention of stroke,” Tohoku J. Exp. Med., 157, No. 4, 337–343 (1989).PubMedCrossRefGoogle Scholar
  55. 55.
    D. J. Son, M. R. Cho, Y. R. Jim, et al., “Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway,” Prost. Leukot. Essent. Fatty Acids, 71, No. 1, 25–31 (2004).CrossRefGoogle Scholar
  56. 56.
    A. Steptoe, E. L. Gibson, R. Vuononvirta, et al., “The effects of chronic tea intake on platelet activation and inflammation: a doubleblind placebo controlled trial,” Atherosclerosis, 193, No. 2, 277–282 (2007).PubMedCrossRefGoogle Scholar
  57. 57.
    R. Stocker and J. F. Keaney, “Role of oxidative modifications in atherosclerosis,” Physiol. Rev., 84, No. 4, 1381–1478 (2004).PubMedCrossRefGoogle Scholar
  58. 58.
    E. Sürmen-Gür, T. Gülten, Z. Serdar, and M. Colakogullari, “Chronic black tea administration protects plasma proteins, plasma, liver and kidney lipids against oxidation,” Med. Sci. Monit., 12, No. 3, BR102–BR105 (2006).PubMedGoogle Scholar
  59. 59.
    E. Suzuki, T. Yorifuji, S. Takao, et al., “Green tea consumption and mortality among Japanese elderly people: the prospective Shizuoka elderly cohort,” Ann. Epidemiol., 129, No. 10, 732–739 (2009).CrossRefGoogle Scholar
  60. 60.
    J.-I. Suzuki, M. Ogawa, A. Izawa, et al., “Dietary consumption of green tea catechins attenuate hyperlipidaemia-induced atherosclerosis and systemic organ damage in mice,” Acta Cardiologica, 60, No. 3, 271–276 (2005).PubMedCrossRefGoogle Scholar
  61. 61.
    J.-I. Suzuki, M. Ogawa, H. Futamatsu, et al., “Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation and fibrosis, and alter cytokine expression in rat autoimmune myocarditis,” Eur. J. Heart. Failure, 9, No. 2, 152–159 (2007).CrossRefGoogle Scholar
  62. 62.
    J.-I. Suzuki, M. Isobe, R. Morishita, and R. Nagai, “Tea polyphenols regulate key mediators on inflammatory cardiovascular disease,” Mediat. Inflam., ID 494928 (2009).Google Scholar
  63. 63.
    N. Tanabe, H. Suzuki, Y. Aizawa, and N. Seki, “Consumption of green and roasted teas and the risk of stroke incidence: results from the Tokamachi-Nakasato cohort study in Japan,” Int. J. Epidemiol., 37, No. 5, 1030–1040 (2008).PubMedCrossRefGoogle Scholar
  64. 64.
    T. Terashima, J. Takido, and H. Yokogoshi, “Time-dependent changes of amino acids in the serum, liver, brain and urine of rats administrated with theanine,” Biosci. Biotechnol. Biochem., 63, No. 4, 615–618 (1999).PubMedCrossRefGoogle Scholar
  65. 65.
    A. G. Thrift, J. J. McNeil, A. Forbes, and G. A. Donnan, “Risk factors for cerebral hemorrhage in the era of well-controlled hypertension. Melbourne Risk Factor Study (MERFS) Group,” Stroke, 27, 2020–2025 (1996).PubMedCrossRefGoogle Scholar
  66. 66.
    U. J. Unachukwu, S. Ahmed, A. Kavalier, et al., “White and green teas (Camellia sinensis var. sinensis): variation in phenolic, methylxanthine, and antioxidant profiles,” J. Food Sci., 75, No. 6, C541–C548 (2010).PubMedCrossRefGoogle Scholar
  67. 67.
    J. A. Vinson, K. Teufel, and N. Wu, “Green and black teas inhibit atherosclerosis by lipid, antioxidant, and fibrinolytic mechanisms,” J. Agric. Food Chem., 52, No. 11, 3661–3665 (2004).PubMedCrossRefGoogle Scholar
  68. 68.
    Q. M. Wang, Q. Y. Gong, J. J. Yan, et al., “Association between green tea intake and coronary artery disease in a Chinese population,” Circ. J., 74, No. 2, 294–300 (2010).PubMedCrossRefGoogle Scholar
  69. 69.
    J. Weinberger, “Prevention of ischemic stroke,” Curr. Cardiol. Rep., 4, No. 2, 164–171 (2002).PubMedCrossRefGoogle Scholar
  70. 70.
    J. L. Witztum and D. Steinberg, “Role of oxidized low density lipoprotein in atherogenesis,” J. Clin. Invest., 88, No. 6, 1785–1792 (1991).PubMedCentralPubMedCrossRefGoogle Scholar
  71. 71.
    R. M. Wolfram, A. Oguogho, Y. Efthimiou, et al., “Effect of black tea on (iso)-prostaglandins and platelet aggregation in healthy volunteers,” Prost. Leukotr. Essent. Fatty Acids, 66, No. 5–6, 529–533 (2002).Google Scholar
  72. 72.
    L. Yochum, L. H. Kushi, K. Meyer, and A. R. Folsom, “Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women,” Am. J. Epidemiol., 149, 943–949 (1999).PubMedCrossRefGoogle Scholar
  73. 73.
    J.-M. Yun, I. Jialal, and S. Devaraj, “Effects of epigallocatechin gallate on regulatory T cell number and function in obese v. Lean volunteers,” Brit. J. Nutr., 103, 1771–1777 (2010).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Academician I. P. Pavlov St. Petersburg State Medical UniversitySt. PetersburgRussia
  2. 2.V. A. Almazov Federal Heart, Blood, and Endocrinology CenterSt. PetersburgRussia

Personalised recommendations